Journal of Critical Care
Volume 25, Issue 2 , Pages 270-275 , June 2010

Troponin-I as a prognosticator of mortality in severe sepsis patients

  • Jijo John, MD

      Affiliations

    • University of Oklahoma Health Sciences Center, Pulmonary/Critical Care Medicine, Oklahoma City, OK 73104, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 405 271 6173; fax: +1 405 271 5892.
    • ,
  • D. Bradley Woodward, MD

      Affiliations

    • Eli Lilly and Company, Cardiovascular/Critical Care, Lilly Corporate Center, Indianapolis, IN 46285, USA
    • ,
  • Yanping Wang, PhD

      Affiliations

    • Eli Lilly and Company, Cardiovascular/Critical Care, Lilly Corporate Center, Indianapolis, IN 46285, USA
    • ,
  • S. Betty Yan, PhD

      Affiliations

    • Eli Lilly and Company, Cardiovascular/Critical Care, Lilly Corporate Center, Indianapolis, IN 46285, USA
    • ,
  • Diana Fisher, MS

      Affiliations

    • Eli Lilly and Company, Cardiovascular/Critical Care, Lilly Corporate Center, Indianapolis, IN 46285, USA
    • ,
  • Gary T. Kinasewitz, MD

      Affiliations

    • University of Oklahoma Health Sciences Center, Pulmonary/Critical Care Medicine, Oklahoma City, OK 73104, USA
    • ,
  • Darell Heiselman, DO

      Affiliations

    • Eli Lilly and Company, Cardiovascular/Critical Care, Lilly Corporate Center, Indianapolis, IN 46285, USA

References 

  1. McLean AS, Huang SJ, Salter M. Bench-to bedside review: the value of cardiac biomarkers in the intensive care patient. Crit Care. 2008;12:215
  2. Collinson P, Gaze D. Cardiac troponins in intensive care. Crit Care. 2005;9:345–346
  3. Fromm R. Cardiac troponins in the intensive care unit: common causes of increased levels and interpretation. Crit Care Med. 2007;35:584–588
  4. Alpert JS, Thygesen K, Antman E, et al. Myocardial infarction redefined—a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol. 2000;36:959–969
  5. Ammann P, Fehr T, Minder EI, et al. Elevation of troponin I in sepsis and septic shock. Intensive Care Med. 2001;27:965–969
  6. Arlati S, Brenna S, Prencipe L, et al. Myocardial necrosis in ICU patients with acute non-cardiac disease: a prospective study. Intensive Care Med. 2000;26:31–37
  7. John J, Awab A, Norman D, et al. Activated protein C improves survival in severe sepsis patients with elevated troponin. Intensive Care Med. 2007;33:2122–2128
  8. Mannam P, Devarakonda VS, Wittbrodt ET, et al. Association of troponin I concentrations with outcomes in sepsis. Chest. 2004;865S:126
  9. Maeder M, Fehr T, Rickli H, et al. Sepsis-associated myocardial dysfunction: diagnostic and prognostic impact of cardiac troponins and natriuretic peptides. Chest. 2006;129:1349–1366
  10. Sands KE, Bates DW, Lanken PN, et al. Academic Medical Center Consortium Sepsis Project Working Group. Epidemiology of sepsis syndrome in 8 academic medical centers. JAMA. 2007;278:234–240
  11. Miniño AM, Heron MP, Murphy SL, et al. Disease Control and Prevention National Center for Health Statistics National Vital Statistics System. Deaths: final data for 2004. Natl Vital Stat Rep. 2007;55:1–119
  12. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001;29:1303–1310
  13. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;344:699–709
  14. Heiselman DE, Woodward DB, Wang Y, Fisher DL, Kinasewitz G, John J. Troponin as a prognosticator of mortality in severe sepsis patients. Crit Care Med. 2008;36(12 Suppl):A160
  15. ver Elst KM, Spapen HD, Nguyen DN, et al. Cardiac troponins I and T are biological markers of left ventricular dysfunction in septic shock. Clin Chem. 2000;46:650–657
  16. Ammann P, Maggiorini M, Bertel O, et al. Troponin as a risk factor for mortality in critically ill patients without acute coronary syndromes. J Am Coll Cardiol. 2003;41:2004–2009
  17. Fernandes CJ, Akamine N, Knobel E. Cardiac troponin: a new serum marker of myocardial injury in sepsis. Intensive Care Med. 1999;25:1165–1168
  18. Spies C, Haude V, Fitzner R, et al. Serum cardiac troponin T as a prognostic marker in early sepsis. Chest. 1998;113:1055–1063
  19. Turner A, Tsamitros M, Bellomo R. Myocardial cell injury in septic shock. Crit Care Med. 1999;27:1775–1780
  20. Mehta NJ, Khan IA, Gupta V, et al. Cardiac troponin I predicts myocardial dysfunction and adverse outcome in septic shock. Int J Cardiol. 2004;95:13–17
  21. Scott EC, Ho HC, Yu M, et al. Pre-existing cardiac disease, troponin I elevation and mortality in patients with severe sepsis and septic shock. Anaesth Intensive Care. 2008;36:515–519
  22. Esmon CT. The protein C pathway. Chest. 2003;124(3 Suppl):26S–32S
  23. Lim W, Qushmag I, Devereaux PJ, et al. Elevated cardiac troponin measurements in critically ill patients. Arch Inten Med. 2006;166:2446–2454
  24. Stein R, Gupta B, Agarwal S, et al. Prognostic implications of normal (<0.10 ng/ml) and borderline (0.10 to 1.49 ng/ml) troponin elevation levels in critically ill patients without acute coronary syndrome. Am J Cardiol. 2008;102:509–512

☆ Work was performed at Eli Lilly and Company, Cardiovascular/Critical Care, Lilly Corporate Center, Indianapolis, IN 46285.

☆☆ Financial support was provided by Eli Lilly and Company.

★ Disclosures: Dr Kinasewitz is a speaker for Eli Lilly's lecture bureau. Drs Woodward, Wang, Yan, and Heiselman and Ms Fisher are employees and shareholders of Eli Lilly and Company. Eli Lilly and Company is the maker of drotrecogin alfa (activated).

PII: S0883-9441(09)00287-1

doi: 10.1016/j.jcrc.2009.12.001

Journal of Critical Care
Volume 25, Issue 2 , Pages 270-275 , June 2010

Article Tools